A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
NCT06702449
This study is recruiting at 6 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to assess safety, reactogenicity, and immune response of the candidate UTI vaccine compared to placebo in adults between and including 18-64 years of age (YOA), and to perform a preliminary evaluation of clinical efficacy in females between and including 18-64 YOA.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Urinary Tract Infections
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 to 64 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- GlaxoSmithKline
- Last updated on ClinicalTrials.gov
- April 21, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Kansas · 1
- GSK Investigational Site · Lenexa, KS
New Jersey · 1
- GSK Investigational Site · Secaucus, NJ
New York · 1
- GSK Investigational Site · Rochester, NY
Texas · 1
- GSK Investigational Site · Weatherford, TX
Washington · 2
- GSK Investigational Site · Seattle, WA
- GSK Investigational Site · Wenatchee, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.